Mistakes Made: FDA Acknowledges Lilly Phoned to Question Sanjay Kaul's Inclusion on Prasugrel Panel
23 februari 2009
Prior to the February 3, 2009 Food and Drug Administration advisory panel hearing on prasugrel (Lilly/Daiichi Sankyo), the drug's sponsor called the agency to question the inclusion of Dr Sanjay Kaul (Cedars-Sinai Medical Center, Los Angeles, CA) on the Cardiovascular and Renal Drugs Advisory Committee, heartwire has learned.
Bron: Medscape
| < Vorige | Volgende > |
|---|
